Lung Cancer Knowledge Hub

Hsa_circ_0046263 A Promoting Factor of NSCLC

The circular RNA hsa_circ_0046263 drives carcinogenesis and metastasis of non-small cell lung cancer (NSCLC), according to a study, which appeared in Cancer Management and...

Assessing One-Year QoL Trends in Early-Stage Lung Cancer Patients After Lobectomy

A study that appeared in Frontiers in Psychology sought to identify one-year trends of quality of life (QoL) in patients with lung cancer. Researchers analyzed...

Guanylate-Binding Protein 1 as a Prognostic Marker in Lung Cancer

Guanylate-binding protein 1 (GBP1) might be a prognostic biomarker in lung adenocarcinoma, according to a study published in the Journal of Clinical Laboratory Analysis. In...

Molecules Involved in Malignant Pleural Effusion of Non-Small Cell Lung Cancer

A study identified more than five molecules involved in the formation of malignant pleural effusions (MPEs), which deteriorate the quality of life in patients...

Decreased Muscle Mass Predicts the Efficacy of Immunotherapy for Advanced Non-Small Cell Lung Cancer

Skeletal muscle mass loss may predict the therapeutic effects of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC), according to...

Hem/Onc Roundup: Experts Discuss Phase 2 Trial of NSCLC Treatment, and More

Is Myeloma Development Associated With Blood Type? ABO blood groups may play a role in the development and outcomes of multiple myeloma, according to new...

Dr. Camidge Discusses Launch of Phase 2 Trial Evaluating RAF/MEK Inhibitor in NSCLC

Verastem Oncology recently announced the initiation of the second phase 2 registration-directed clinical trial from its RAMP (Raf And Mek Program). The study, RAMP...

Journal Reading List

Advertisement
Advertisement